PCRX Q3 2022 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$167M+31.1% YoY

Gross Profit

$117M69.7% margin

Operating Income

$21M12.7% margin

Net Income

-$693,000-0.4% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$37M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$964M

Stockholders' Equity

$770M

Cash & Equivalents

$109M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$128M	+31.1%
Gross Profit	$117M	$93M	+25.5%
Operating Income	$21M	$31M	-32.3%
Net Income	-$693,000	$18M	-103.9%

Revenue Segments

Product

$167M51%

EXPAREL/bupivacaine liposome injectable suspension

$133M40%

ZILRETTA

$26M8%

Bupivacaine Liposome Injectable Suspension

$3M1%